Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
4 days ago
Video Series
Added:
1 year ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more
Added:
1 month ago
Source:
Arrhythmia and Electrophysiology Review
Conduction system pacing has emerged as a potential alternative to conventional biventricular pacing (BiVP) for delivering cardiac resynchronization therapy (CRT). The recent LEFT-BUNDLE-CRT trial aimed to determine if left-bundle branch area pacing (LBBAP) is non-inferior to BiVP in patients with guideline-based indications for CRT and left-bundle branch block (LBBB).¹MethodologyThe LEFT-BUNDLE…
View more
Added:
2 years ago
CRT 2024 — Prof Patrick W Serruys (National University of Ireland, Galway, US) joins us to discuss learning from the SYNTAX trial.The SYNTAX trial is a randomized controlled trial designed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents versus coronary artery bypass grafting (CABG) in patients with complex coronary…
View more
Added:
1 year ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical…
View more
Added:
1 year ago
CRT 25 - Insights on the progression risk in patients with mild to moderate aortic stenosis (AS) show that there was no significant difference in progression rates between mild and moderate AS. However, moderate AS patients had significantly higher mortality rates than mild AS patients at one- and two-year follow ups. The study also suggests that elevated phosphate levels and elevated…
View more
Added:
1 month ago
Added:
2 weeks ago
Added:
1 month ago
Added:
1 month ago